ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Illinois » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Illinois

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
IN HUH M.D.

Cardiovascular Disease

20,927

$1.78M

282
263 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

20%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

41%
prescriptions for brand name drugs

Avg: 25%

$85
Average prescription price

Avg: $65

THANAD SHAY M.D.

Cardiovascular Disease

14,973

$603K

442
411 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 25%

$40
Average prescription price

Avg: $65

NAEEM KHAN MD

Cardiovascular Disease

14,476

$552K

488
390 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 25%

$38
Average prescription price

Avg: $65

LOKESH CHANDRA M.D.

Cardiovascular Disease

13,475

$802K

557
395 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 25%

$59
Average prescription price

Avg: $65

JOHN MONTEVERDE M.D.

Cardiovascular Disease

13,333

$997K

406
325 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 25%

$75
Average prescription price

Avg: $65

VIJAY HARYANI MD, FACC

Cardiovascular Disease

11,986

$653K

923
810 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$54
Average prescription price

Avg: $65

HATIM MAHMOOD M.D.

Cardiovascular Disease

10,394

$669K

529
457 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 25%

$64
Average prescription price

Avg: $65

SAFDAR ALI MD

Cardiovascular Disease

10,031

$642K

289
207 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 25%

$64
Average prescription price

Avg: $65

ATUL SHAH M.D.

Cardiovascular Disease

9,806

$491K

740
655 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 25%

$50
Average prescription price

Avg: $65

PREDRAG SIMOVIC MD

Cardiovascular Disease

9,290

$538K

307
263 are 65+

5%
patients receiving schedule two controlled substances

Avg: 0%

13%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 25%

$58
Average prescription price

Avg: $65

AMER HUSSEINI MD

Cardiovascular Disease

9,185

$389K

361
292 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 25%

$42
Average prescription price

Avg: $65

TAHIR ABBASI M.D.

Cardiovascular Disease

9,148

$516K

314
248 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

19%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 25%

$56
Average prescription price

Avg: $65

MADHUSUDAN VALLALA MD

Cardiovascular Disease

8,156

$389K

180
150 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

21%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$48
Average prescription price

Avg: $65

MOHAMMAD VAKASSI MD

Cardiovascular Disease

7,680

$263K

509
465 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 25%

$34
Average prescription price

Avg: $65

MOHAMMED HASEEB M.D.

Cardiovascular Disease

7,671

$387K

364
311 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 25%

$50
Average prescription price

Avg: $65

NICOLAOS ABARIOTIS MD

Cardiovascular Disease

7,585

$483K

455
413 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 25%

$64
Average prescription price

Avg: $65

BRONISLAW ORAWIEC

Cardiovascular Disease

7,565

$489K

307
264 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 25%

$65
Average prescription price

Avg: $65

LAXMAN IYER M.D.

Cardiovascular Disease

7,496

$339K

248
224 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 25%

$45
Average prescription price

Avg: $65

SUBHASH PATEL M.D.

Cardiovascular Disease

7,367

$280K

674
606 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 25%

$38
Average prescription price

Avg: $65

MANOHAR KOLA M.D.

Cardiovascular Disease

7,343

$246K

664
568 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 25%

$33
Average prescription price

Avg: $65

DAVID WALLACE M.D.

Cardiovascular Disease

7,150

$287K

475
408 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 25%

$40
Average prescription price

Avg: $65

GALINA SABIR MD

Cardiovascular Disease

7,002

$617K

211
142 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

31%
patients receiving schedule three controlled substances

Avg: 1%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 25%

$88
Average prescription price

Avg: $65

MUHAMMAD MUSHTAQ MD

Cardiovascular Disease

6,961

$248K

239
174 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

27%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 25%

$36
Average prescription price

Avg: $65

ROOP LAL M.D.

Cardiovascular Disease

6,913

$320K

445
383 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 25%

$46
Average prescription price

Avg: $65

MADAN GUPTA MD

Cardiovascular Disease

6,910

$327K

248
235 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$47
Average prescription price

Avg: $65

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank